Copyright
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Cardiol. Nov 26, 2024; 16(11): 651-659
Published online Nov 26, 2024. doi: 10.4330/wjc.v16.i11.651
Published online Nov 26, 2024. doi: 10.4330/wjc.v16.i11.651
Cardiac hypertrophy in polycythemia vera: A case report and review of literature
Bai-Sheng Ma, Shu-Hui Zhai, Wei-Wei Chen, Qi-Ni Zhao, Department of Cardiology, China-Japan Union Hospital of Jilin University, Changchun 130031, Jilin Province, China
Bai-Sheng Ma, Shu-Hui Zhai, Wei-Wei Chen, Qi-Ni Zhao, Department of Cardiology, Jilin Provincial Cardiovascular Research Institute, Changchun 130031, Jilin Province, China
Bai-Sheng Ma, Shu-Hui Zhai, Wei-Wei Chen, Qi-Ni Zhao, Department of Cardiology, Jilin Provincial Engineering Laboratory for Endothelial Function and Genetic Diagnosis of Cardiovascular Disease, Changchun 130031, Jilin Province, China
Co-corresponding authors: Wei-Wei Chen and Qi-Ni Zhao.
Author contributions: Ma BS wrote the first draft and corrected the manuscript; Ma BS and Zhai SH collected the data; Chen WW and Zhao QN revised and contributed equally to the manuscript and figures as co-corresponding authors; all authors have read and approved the final manuscript.
Supported by Jilin Province Health Research Talent Special Project , No. 2020SCZ27 .
Informed consent statement: Written informed consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist (2016).
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Wei-Wei Chen, MD, Attending Doctor, Department of Cardiology, China-Japan Union Hospital of Jilin University, No. 126 Xiantai Street, Changchun 130031, Jilin Province, China. chenweiwei@jlu.edu.cn
Received: July 28, 2024
Revised: September 1, 2024
Accepted: October 8, 2024
Published online: November 26, 2024
Processing time: 94 Days and 17.8 Hours
Revised: September 1, 2024
Accepted: October 8, 2024
Published online: November 26, 2024
Processing time: 94 Days and 17.8 Hours
Core Tip
Core Tip: Clinicians should be highly vigilant regarding the risk of thrombosis and cardiovascular complications when managing patients with polycythemia vera (PV). In young patients with hypertension, who have excluded common secondary causes and have difficult-to-control blood pressure, there should be an alert for PV. The coexistence of PV and myocardial hypertrophy is rarely reported. The myocardial hypertrophy observed in this case, which is difficult to explain for other reasons, proposes a new hypothesis that PV may be a potential trigger. Cytoreductive therapy may be an important factor in improving the patient’s myocardial hypertrophy.